DBVT vs. AGEN, MOLN, VXRT, OMGA, CLLS, CRDL, ZURA, LIFE, SCLX, and BCAB
Should you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include Agenus (AGEN), Molecular Partners (MOLN), Vaxart (VXRT), Omega Therapeutics (OMGA), Cellectis (CLLS), Cardiol Therapeutics (CRDL), Zura Bio (ZURA), aTyr Pharma (LIFE), Scilex (SCLX), and BioAtla (BCAB). These companies are all part of the "biological products, except diagnostic" industry.
DBV Technologies (NASDAQ:DBVT) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
DBV Technologies has higher earnings, but lower revenue than Agenus. DBV Technologies is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.
71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 0.7% of DBV Technologies shares are held by insiders. Comparatively, 4.8% of Agenus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Agenus had 4 more articles in the media than DBV Technologies. MarketBeat recorded 6 mentions for Agenus and 2 mentions for DBV Technologies. Agenus' average media sentiment score of 0.87 beat DBV Technologies' score of 0.00 indicating that Agenus is being referred to more favorably in the news media.
DBV Technologies presently has a consensus price target of $5.00, indicating a potential upside of 625.22%. Agenus has a consensus price target of $130.00, indicating a potential upside of 1,466.27%. Given Agenus' stronger consensus rating and higher probable upside, analysts plainly believe Agenus is more favorable than DBV Technologies.
DBV Technologies has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Agenus has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Agenus received 65 more outperform votes than DBV Technologies when rated by MarketBeat users. Likewise, 70.05% of users gave Agenus an outperform vote while only 57.35% of users gave DBV Technologies an outperform vote.
Agenus has a net margin of -164.69% compared to DBV Technologies' net margin of -461.32%. Agenus' return on equity of 0.00% beat DBV Technologies' return on equity.
Summary
Agenus beats DBV Technologies on 13 of the 18 factors compared between the two stocks.
Get DBV Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DBV Technologies Competitors List
Related Companies and Tools
